Compare Ecopetrol SA (EC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Novavax Inc — how do they compare? Ecopetrol SA trades at $17.18 (market cap $33.11B), while Novavax Inc trades at $12.42 (market cap $1.82B). The key difference: Ecopetrol SA is far larger — about 18.2× Novavax Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Novavax Inc for 59 Days on average.
| EC | NVAX | |
|---|---|---|
Market Cap | $33.11B | $1.82B |
Volume | 993,598 | 6,198,505 |
Sector | Energy | Health |
52-Week High | $18.26 | $12.56 |
52-Week Low | $8.61 | $6.22 |
Typical Hold Time | 84 Days | 59 Days |
Enterprise Value | $61.36B | $1.39B |
Dividend Yield | 3.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.63, down 1.95% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 7.97 and P/S of 0.91, but faces declining revenue trends from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while analyst sentiment remains cautious with 27% buy ratings.
The outlook remains challenged by declining profitability and political interference risks, though current valuations appear discounted. Investment opportunity exists if new management can stabilize operations, but investors face headwinds from earnings volatility and geopolitical factors in Colombia's state-controlled energy sector.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
